Sign In
Buy MNPR
$60.56
-0.700 (-1.14%)
At Close: Jun 03, 2026
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treat
Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout
01:15pm, Monday, 15'th Sep 2025
Monopar Therapeutics unveiled promising results Monday from three key studies, leading the top 1% biotech stock to break out of a cup base.
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treat
Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent
10:29am, Thursday, 04'th Sep 2025
Monopar Therapeutics Inc. is a clinical-stage biotech with two promising programs: ALXN1840 for Wilson disease and a radiopharmaceuticals pipeline targeting advanced cancers. ALXN1840 has shown superi
WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innov
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
08:00am, Tuesday, 12'th Aug 2025
WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing inno
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
11:00am, Wednesday, 11'th Jun 2025
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to a 51.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
07:00am, Wednesday, 11'th Jun 2025
WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmaceut
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
07:00am, Tuesday, 03'rd Jun 2025
WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing inno
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
08:00am, Tuesday, 13'th May 2025
WILMETTE, Illinois, May 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing i
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
02:30am, Wednesday, 07'th May 2025
WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unm
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
08:00am, Tuesday, 29'th Apr 2025
WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with un
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
08:00am, Monday, 31'st Mar 2025
WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with un
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
09:50am, Friday, 21'st Mar 2025
Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
01:10pm, Thursday, 23'rd Jan 2025
Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease NORTH CHICAGO, Ill. , Jan. 23, 2025 /PRNewswir
